Loading stock data…
INGN
$6.98-0.13 (-1.83%)
Market ClosedLast close May 1
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Inogen, Inc. in the Healthcare sector is trading at $6.98. The stock is currently 24% below its 52-week high of $9.13, remaining 0.7% below its 200-day moving average. Technical signals show neutral RSI of 61 and bullish MACD crossover, explaining why INGN maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.98
Potential Upside
5%
Whystock Fair Value$7.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen thera...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$193.89M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.55%
Volume
Today's trading volume
172,663
Recent News
We're Not Very Worried About Inogen's (NASDAQ:INGN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN rides surging POC demand and global growth tailwinds, but U.S. channel shifts and macro risks may weigh on near-term performance.
Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates
Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +8.24% and -0.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Inogen Unveils Growth Plan at Needham Conference: New CFO, Voxi 5, Simeox and Aurora Mask Push
Inogen (NASDAQ:INGN) executives used a fireside chat at the 25th Annual Needham Healthcare Conference to outline the company’s strategic priorities, discuss its product expansion beyond portable oxygen concentrators, and address recent financial trends. The session was hosted by Needham & Compan
Inogen (INGN) Surges 6.9%: Is This an Indication of Further Gains?
Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.